Shanghai: Novariti drift from research to drug development

ZURICH (Reuters)–Novartis is drifting away from drug discovery at its Shanghai base and turning its attention to drug development, stating that rising approvals in China are forcing the Swiss company to redirect its assets for marketing its medicines.

The transition marks a possible upside-down from just three years ago when Novartis christened the $1 billion campus as its early-stage research center in China.

Approxi....